Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.
| Revenue (TTM) | $2.71B |
| Gross Profit (TTM) | $510.90M |
| EBITDA | $69.90M |
| Operating Margin | 0.52% |
| Return on Equity | -64.50% |
| Return on Assets | -0.05% |
| Revenue/Share (TTM) | $29.42 |
| Book Value | $5.56 |
| Price-to-Book | 3.45 |
| Price-to-Sales (TTM) | 0.72 |
| EV/Revenue | 1.029 |
| EV/EBITDA | 92.35 |
| Quarterly Earnings Growth (YoY) | -57.40% |
| Quarterly Revenue Growth (YoY) | -2.30% |
| Shares Outstanding | $94.58M |
| Float | $93.71M |
| % Insiders | 1.02% |
| % Institutions | 110.78% |
Volatility is currently expanding
Fortrea NASDAQ: FTRE reported second-quarter 2026 revenue of $678.2 million and adjusted EBITDA of $58.7 million, while raising its full-year revenue and adjusted EBITDA outlook. Management said results reflected stronger clinical pharmacology performance, cost-savings initiatives and improving commercial activity, particularly among biotechnology clients.
Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.19 per share a year ago.
Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Fortrea Holdings Inc. (Nasdaq: FTRE) (“Fortrea”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/fortrea-holdings/ Recently a securities fraud complaint was filed against Fortrea on behalf of certain investors who purchased shares of the company's stock between July 5, 2023 and February 28, 2025 (the “Wrongdoing Period”). Accor.
DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026.
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
DEC, FTRE, HG, PARR and KE have been added to the Zacks Rank #1 (Strong Buy) List on July 7, 2026.
Jason Knoblauch will succeed Jill McConnell as chief financial officer of Fortrea Jason Knoblauch will succeed Jill McConnell as chief financial officer of Fortrea
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) on June 10, 2026, to 10 newly hired employees. The award consisted of 240,500 RSUs that vest in three equal annual installments starting June 10, 2027, subject to the employee's continuous employment through the applicable vesting date. The RSUs are subject to the terms and conditions of the Company's Amended and Restated 2025 Inducement Award Plan and the award agreements covering the grants. These awards follow Nasdaq Listing Rule 5635(c)(4) and are intended as an inducement material to the individual becoming a new employee of the Company.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FTRE and any ticker you trade — then tracks every position and per-strategy win rate.
